Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Natera Inc. Common Stock — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.16 (market cap $140.85M), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 404.9× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Natera Inc. Common Stock for 0 Days on average.
| KOLD | NTRA | |
|---|---|---|
Market Cap | $140.85M | $57.03B |
Volume | 6,606,542 | 1,131,157 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $425.64 |
52-Week Low | $13.58 | $179.42 |
Typical Hold Time | 10 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $23.85, down 5.06% over the past 24 hours amid bearish technical signals. The stock shows significant selling pressure with 16 sell signals versus 1 buy signal across technical indicators. Natural gas market fundamentals remain challenging with record-high U.S. production reported by the EIA in July 2026, while geopolitical tensions in the Middle East create volatility in energy markets.
The outlook remains cautious as technical indicators point to continued downward momentum. Investment opportunities exist for contrarian investors given the oversold RSI reading, but risks include persistent natural gas price weakness and high production levels that may pressure energy sector performance in the near term.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
